Dive Brief:
- Neurent Medical has raised 62.5 million euros ($74 million) to commercialize a device that treats a common nasal condition, the company said Wednesday.
- The Series C financing will equip Neurent to expand commercialization of a product that delivers radiofrequency energy to treat chronic rhinitis symptoms such as nasal congestion.
- Neurent received Food and Drug Administration clearance for the latest version of the device, sold as Neuromark, last year.
Dive Insight:
Neuromark delivers low-power radiofrequency to create lesions that affect nasal nerves. By disrupting parasympathetic nerve signals, the lesions can reduce symptoms of allergic and nonallergic rhinitis such as nasal congestion and runny nose.
In a two-year study, Neurent reported a 55% reduction in the mean reflective Total Nasal Symptom Score from baseline. The score assesses congestion, rhinorrhea, sneezing and itching. Neurent saw significant improvements in all four areas, as well as in postnasal drip and cough. Patients reported better quality of life after undergoing treatment.
Neuromark received 510(k) clearance in 2021. The FDA cleared updated versions of the device in 2022 and 2025.
Having received a reimbursement code at the start of 2024, Neurent secured expanded coverage for Neuromark last year. Cigna stopped classifying the procedure code as experimental and investigational in September 2025, increasing access to the device. UnitedHealthcare’s Medicare Advantage policy took the same action a month later.
With millions of patients gaining access to Neuromark, investors have backed Neurent’s plans to step up commercialization of the device. MVM Partners led the investment in the Irish medtech company and Sofinnova Partners was a significant participant in the round. Existing investors EQT Life Sciences, Atlantic Bridge, Fountain Healthcare Partners and Enterprise Ireland also participated in the financing.
The investment reflects Neuromark’s potential to address a condition that affects millions of people and has limited effective treatment options. Neurent said one in four adults experiences chronic rhinitis, a condition that can be caused by overactive nerves that drive mucus production.
